Rein Therapeutics Inc. (RNTX)

Market Cap	30.30M
Revenue (ttm)	n/a
Net Income (ttm)	-59.15M
Shares Out	23.31M
EPS (ttm)	-2.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,973
Open	1.360
Previous Close	1.370
Day's Range	1.280 - 1.381
52-Week Range	1.040 - 4.400
Beta	1.14
Analysts	Buy
Price Target	10.00 (+669.23%)
Earnings Date	Nov 13, 2025

About RNTX

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: RNTX
• Website: https://www.reintx.com

Analyst Summary

According to 2 analysts, the average rating for RNTX stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 669.23% from the latest price.

Price Target

$10.0

(669.23% upside)

Analyst Consensus: Buy